# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Paul Robeson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML048-SYN-TD
- Date: 1957-08-24
- Fictional facility: St. Posthumous Health Center
- Fictional author: Theodore Bankole-Ashworth, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Twenty-four-week review of depression treatment. **S**

## History of present illness

Mr. Robeson returns eleven weeks after the switch to venlafaxine; he has taken 225 mg each morning for seven weeks. He sleeps five and a half hours, walks every morning, and has begun to read and see one or two old friends, but he still has little pleasure in music and has not sung in public. The cough from four weeks ago has gone. He sweats a little more than before. He has had no thoughts of suicide since the spring and no elation. He has completed sixteen behavioral activation sessions and continues fortnightly with his psychologist, who reports PHQ-9 scores in the low to mid teens. He asked what else can be done, including whether he would need shock treatment. **S**

| Element | Detail |
|---|---|
| Medicines | Venlafaxine 225 mg for seven weeks, eleven weeks in all |
| Mood | PHQ-9 13 from 22: partial response |
| Side effects | Mild sweating; blood pressure 134/84 |
| Question | What else can be done, including ECT |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Mild sweating; weight 101.0 kg |
| Psychiatric | Positive | Low mood on most days, little pleasure in music; no thoughts of suicide; no elation |
| Respiratory | Negative | Cough gone |
| Cardiovascular | Negative | No palpitations or headache |
| Neurological | Negative | No memory complaint or tremor |

5 systems reviewed. **S**

## Current medications

- Venlafaxine extended-release 75 mg capsules, three capsules (225 mg) each morning with food **S**
- Aripiprazole 2 mg tablet, one tablet each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 134/84 mmHg; pulse 78 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 101 kg; BMI 28 kg/m². All vital signs are synthetic.

Sodium: 136 mmol/L; Glucose: 94 mg/dL; Hemoglobin A1c: 5.6%; Total cholesterol: 204 mg/dL (high); HDL cholesterol: 46 mg/dL; Triglycerides: 130 mg/dL; LDL cholesterol (calculated): 132 mg/dL (high); PHQ-9: 13; MoCA: 28. All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 136 mmol/L at this visit **S**
- Glucose: 92 mg/dL at baseline, 94 mg/dL at this visit **S**
- Hemoglobin A1c: 5.6% at baseline, 5.6% at this visit **S**
- PHQ-9: 22 at baseline, 13 at this visit **S**
- MoCA: 28 at baseline, 28 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Weight 101.0 kg, BMI 28.0; blood pressure 134/84, pulse 78 |
| Neurological | No tremor, rigidity or abnormal movements; abnormal involuntary movement examination normal |
| Psychiatric | Less slowed; affect a little fuller; logical; no thoughts of suicide |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Treatment-resistant recurrent major depression** (F33.2). PHQ-9 22 to 13 after a second adequate trial, of a different class: a partial response without remission, so the depression is treatment-resistant. Sodium 136; blood pressure 134/84, a small rise on venlafaxine that does not need a change. MoCA 28, unchanged. Safety reviewed: no thoughts of suicide; medicines locked; 988 in his phone. Options were discussed with him and with Dr. Lindqvist-Adebayo: augmentation with aripiprazole, lithium or a second antidepressant; ECT; rTMS; and esketamine nasal spray. For ECT, informed consent was discussed as a conversation, not a form: it is given under general anesthesia with a muscle relaxant and monitoring, usually right unilateral with an ultrabrief pulse to limit memory effects, two or three times a week for a defined course of about six to twelve treatments, with cognitive testing before and during the course; its benefits, risks (anesthesia, headache, muscle aches, and memory loss for events around the course) and alternatives were explained, and he was told he could decline or stop at any time. ECT is not needed now: he has no psychosis, is eating and drinking, and is not suicidal, and he chose augmentation first. Black patients receive ECT less often than white patients with the same diagnosis, so the offer stands on equal terms if augmentation fails. rTMS (daily sessions for about six weeks) and esketamine (twice weekly in the clinic, with blood pressure checks) remain alternatives. **S**
   - Aripiprazole 2 mg each morning, rising to 5 mg in two weeks.
   - Continue venlafaxine 225 mg.
   - Weight at four, eight and twelve weeks; A1c and lipids again at twelve weeks; movement examination in six months.
   - Call for restlessness, stiffness or tremor.
   - ECT, rTMS or esketamine if there is no clear improvement within about eight weeks, or at once if he becomes unable to eat or drink, psychotic or acutely suicidal.
2. **Political persecution and loss of income** (Z60.5). Continuing; he is working with the social worker monthly. **S**
   - Continue social work support.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline and at least monthly during acute treatment (CMID) | Completed today | 13, down 41 percent from 22: partial response; item 9 scored 0 |
| Survey | PHQ-9 between visits, rated by the psychologist at each session | At each therapy session | Completed today | Rated at each session; no positive item 9 reported |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, locked medicines and the 988 Suicide & Crisis Lifeline | Every visit during active treatment | Completed today | No thoughts of suicide since the spring; medicines locked; safety plan reviewed |
| Laboratory | Sodium (SSRI or SNRI in an older adult) | Baseline, about four to six weeks after starting, and with symptoms | Completed today | 136 mmol/L, normal |
| Medication safety | Blood pressure (venlafaxine) | Baseline and at every visit on venlafaxine | Completed today | 134/84, up slightly from 128/80; recheck at each visit |
| Medication safety | Adequacy of the antidepressant trial (dose and duration) | At each review: at least four to eight weeks at an adequate dose before judging response | Completed today | Second adequate trial (seven weeks at 225 mg): partial response; treatment-resistant |
| Medication safety | Adherence and adverse-effect review | Every visit | Completed today | Every dose taken; mild sweating |
| Medication safety | Watch for hypomania or mixed features after starting or changing an antidepressant | Every visit; repeat the MDQ if features emerge | Completed today | No signs of hypomania |
| Survey | Cognitive screen (MoCA) | Baseline, and before and during any course of ECT | Completed today | 28, unchanged; kept as a baseline in case ECT is chosen later |
| Medication safety | ECT informed consent discussion and alternatives (rTMS, esketamine) | When depression is treatment-resistant or severe | Completed today | Discussed; ECT not started now by his choice and because there is no urgent indication; available on equal terms if augmentation fails |
| Self-management | Weight and BMI on aripiprazole | Baseline, 4, 8 and 12 weeks, then quarterly (CMID) | Completed today | Baseline 101.0 kg, BMI 28.0 before aripiprazole |
| Laboratory | Hemoglobin A1c or fasting glucose, and lipids, on aripiprazole | Baseline, 12 weeks, then yearly (CMID) | Completed today | A1c 5.6%, glucose 94 mg/dL; total cholesterol 204, HDL 46, triglycerides 130, LDL 132 mg/dL |
| Examination | Abnormal Involuntary Movement Scale | Baseline, then every six months on an antipsychotic (CMID) | Completed today | Baseline examination normal |
| Referral | Behavioral activation with a psychologist | Weekly for sixteen sessions, then fortnightly | Completed today | Sixteen sessions completed; fortnightly sessions continue |
| Referral | Social work for income and costs | Monthly | Completed today | Monthly meetings continue |

## Goal progress

- Response to treatment: PHQ-9 down by at least half from 22. In progress; target 1957-10-05. **S**
- Remission: PHQ-9 below 5. In progress; target 1957-10-05. **S**
- Stay safe: safety plan in place and reviewed at every visit, with no self-harm. In progress; target 1957-10-05. **S**
- Sing again: daily vocal practice and one public engagement a month. In progress; target 1957-10-05. **S**
- Sleep six to seven hours a night. In progress; target 1957-10-05. **S**

## Medication changes

- Started: Aripiprazole 2 mg tablet, one tablet each morning **S**

## Guideline basis

- APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019), American Psychological Association
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), U.S. Department of Veterans Affairs and Department of Defense
- The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. A Task Force Report of the American Psychiatric Association, 2nd edition (record of the American Journal of Psychiatry review, 2002) (2001), American Psychiatric Association
- The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. A Task Force Report of the American Psychiatric Association, 3rd edition (Library of Congress catalog record, LCCN 2024014438) (2024), American Psychiatric Association Publishing
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), U.S. Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- Williams DR, et al. Prevalence and distribution of major depressive disorder in African Americans, Caribbean blacks, and non-Hispanic whites: results from the National Survey of American Life. Arch Gen Psychiatry 2007;64(3):305-315 (2007), Archives of General Psychiatry (PubMed 17339519)
- Sprenger S, et al. Retrospective Cohort Study of Racial-Ethnic Disparities in Receipt of Electroconvulsive Therapy, 2016-2021. Psychiatr Serv 2025;76(8):736-740 (2025), Psychiatric Services (PubMed 40364636)

## Follow-up

- Nurse phone check in two weeks before the aripiprazole increase. Preventive visit in six weeks with the PHQ-9 and weight. Twelve-week metabolic tests. Call or text 988 at any time in a crisis. **S**
- Next scheduled visit 1957-10-05: periodic adult preventive visit. **S**
